Table 2.

Patient demographics, oncologic history, comorbidities, and outcomes of 25 patients with COVID-19 and ICI therapy

Pt No. *	Age (y)/Sex/ Ethnicity	ICI-Treated Malignancy	Stage	Comorbidities	ICI	Final COVID-19 Status **
1	55/M/White	Melanoma	IV	HTN, hemophilia, hepatitis C, syphilis	Nivolumab	Fully recovered
2	73/F/White	Lung, squamous cell	IVB	HTN, HL, COPD, pulmonary embolism, CHF, CKD, obesity	Pembrolizumab	Died
3	47/F/Black	Breast	IV	Asthma, allergic rhinitis	Nivolumab	Fully recovered
4	81/M/White	Esophageal	IVB	HTN, HL, IBD, peripheral neuropathy, iron deficiency anemia	Pembrolizumab	Died
5	45/M/Hispanic or Latino	Liver	IV	DM	Atezolizumab	Recovered with complications
6	72/F/White	Lung, squamous cell	IV	HTN, HL, COPD, malignant lymphoma, hiatal hernia, low back pain, depression, previous MI, CKD	Pembrolizumab	Died
7	51/F/White	Oropharyngeal	IVA	Celiac disease, anemia, MALT lymphoma	Pembrolizumab	Fully recovered
8	77/F/White	Lung, adenocarcinoma	IV	HTN, COPD, CAD, CHF, CVA, tuberculosis, CKD, obesity	Pembrolizumab	Died
9	74/M/Black	Oropharyngeal, squamous cell	IV	HTN, dementia, HIV, CKD	Pembrolizumab	Died
10	66/F/White	Lung, adenocarcinoma	III	HTN, cirrhosis (porphyria and hepatitis C), obesity, osteopenia, prior DVT, depression	Durvalumab	Fully recovered
11	80/M/White	Acute myelogenous leukemia		MDS, benign prostatic hyperplasia	Ipilimumab	Died
12	71/M/White	Nonmelanoma skin cancer	IV	Asthma, prior DVT, homelessness, pancreatitis, temporal artery hemorrhage, otitis externa	Pembrolizumab	Fully recovered
13	62/F/White	Lung, other	IV	Atrial fibrillation, mitral valve prolapse, iron deficiency anemia	Pembrolizumab	Fully recovered
14	61/M/White	Oropharyngeal squamous cell	IV	HTN, HL	Pembrolizumab	Recovered with complications
15	47/M/White	Oropharyngeal	III	HTN, oral mucositis (radiation induced), GERD, depression, obstructive sleep apnea	Pembrolizumab	Recovered with complications
16	76/M/Hispanic or Latino	Lung, squamous cell	IV	HTN, HL, DM, asthma, COPD, PE, atrial fibrillation, pericardial effusion, prior GI bleed	Nivolumab	Fully recovered
17	74/F/White	Lung, squamous cell	IV	HTN, HL, COPD, PE, PVD, GERD, anxiety	Atezolizumab	Recovered with complications
18	61/M/White	Melanoma	IV	HL, CVA, eczema, psoriasis, Lyme disease, neurosyphilis, neuromyopathy	Pembrolizumab	Fully recovered
19	80/F/White	Lung, adenocarcinoma	IVB	HTN, HL, COPD, atrial fibrillation, obesity, pacemaker, autonomic dysfunction (orthostatic), cytomegalovirus infection, depression, history of breast cancer, history of endometrial cancer, osteoarthritis	Atezolizumab	Recovered with complications
20	75/F/White	Colon	IV	HTN, HL, IBD, GERD, arthritis	Pembrolizumab	Fully recovered
21	66/M/White	Lung, adenocarcinoma	IV	HTN, HL, COPD, CAD, CVA, alcoholism	Pembrolizumab	Recovered with complications
22	83/M/White	Nonmelanoma skin cancer	IV	HTN, HL, atrial fibrillation, prostate cancer, osteoarthritis, lumbar disc disease, GERD, anemia	Cemiplimab	Fully recovered
23	54/M/White	Melanoma	IV	HTN, HL, obesity, cognitive impairment (congenital), hearing loss, ankylosing spondylitis, schizophrenia, sarcoma, psoriasis	Pembrolizumab	Fully recovered
24	75/M/White	Lung, squamous cell	IV	HTN, HL, cardiomyopathy	Pembrolizumab	Died
25	61/F/Other	Oropharyngeal	IVC	HTN, HL, prior PE	Pembrolizumab	Fully recovered

CAD: coronary artery disease; CHF: congestive heart failure; CKD: chronic kidney disease; COPD: chronic obstructive pulmonary disease; COVID-19: coronavirus disease 2019; CVA: cerebrovascular accident; DM: diabetes mellitus; DVT: deep vein thrombosis; GERD: gastric esophageal reflux disease; GI: gastrointestinal; HIV: human immunodeficiency virus; HL: hyperlipidemia; HTN: hypertension; IBD: inflammatory bowel disease; ICI: immune checkpoint inhibitor; IV, stage 4 malignancy; MALT: mucosa-associated lymphoid tissue; MDS: myelodysplastic syndrome; MI: myocardial infarction; PE: pulmonary embolism; Pt: patient; PVD: peripheral vascular disease

^*Age at COVID-19 diagnosis

^**Recovered with complications is defined as patient having a new oxygen requirement even after COVID-19 recovery